A new kind of vaccine may be on the horizon.
Biotech firm Moderna has created a flu vaccine that targets messenger RNA.
The goal is to coax cells to produce their own proteins to fight disease.
A recent test of the vaccine showed sufficient immune response to fight off the flu virus.
Moderna has attracted $1.9 billion in investor interest to continue their work.